alexa Losartan Ointment Relieves Hypertrophic Scars And Keloid: A Pilot Study
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th European Dermatology Congress
June 07-08, 2017 Milan, Italy

Keshvad Hedayatianfard, Ziai S A, Niazi F, Habibi I, Habibi B and Moravvej H
Shahid Beheshti University of Medical Sciences, Iran
ScientificTracks Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554-C1-056
Background: Keloid and hypertrophic scar are two types of fibrosis caused by extracellular matrix overexpression. Angiotensin II via AT1 receptor plays a key role in stimulation and development of collagen production and fibrosis. Less is known about the effects of angiotensin receptor blockers on reducing hypertrophic scar and keloid. It has been reported that expression of angiotensin II receptors is increased during wound healing. Several studies have shown that collagen content expression was inhibited by AT1 antagonists such as losartan. Objective: The purpose of this research was to treat keloid and hypertrophic scar in patients by topical application of losartan potassium ointment. Methods: A pilot single blind placebo-controlled clinical trial was designed and 33 healthy adult volunteers (Keloid=14 and hypertrophic scar=19) were randomly allocated between losartan potassium ointment and placebo groups. The patients used the ointments twice a day for 3 months and were evaluated each month for efficacy and adverse effects. Treatment was evaluated by Vancouver scar scale method before and 3 months after drug application. Results: Out of the 33 patients included, 26 patients completed the treatment course. 7 patients of placebo group left the trial. Nobody left the study because of adverse effects. In losartan group, VSS scores decreased in comparison with placebo group, especially pliability score (p<0.001). No scar return was observed in losartan group 6 months after treatment final time.

Keshvad Hedayatianfard is a PhD student of Pharmacology in Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. His field of interest is fabricating ointment, cream, nano-fiber, hydrogel and wound dressing for wound healing. He has three patents (Iranian patent).

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version